Kristen Jacobsen
Affiliations: | Immunology | University of Colorado Anschutz Medical Campus, Denver, Aurora, CO |
Google:
"Kristen Jacobsen"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lee-Sherick AB, Jacobsen KM, Henry CJ, et al. (2020) MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. Jci Insight. 5 |
| Lee-Sherick AB, Jacobsen KM, Henry CJ, et al. (2018) MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. Jci Insight. 3 |
| Lee-Sherick A, Jacobsen K, Henry CJ, et al. (2018) Mertk Inhibition Promotes Anti-Leukemia Immunity By Reversing T Cell Suppression Via the PD-1 Axis Blood. 132: 4019-4019 |
| DeRyckere D, Lee Sherick AB, Huey MG, et al. (2016) UNC2025, a MerTK small molecule inhibitor, is therapeutically effective alone and in combination with methotrexate in leukemia models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Cook RS, Jacobsen KM, Wofford AM, et al. (2013) MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. The Journal of Clinical Investigation. 123: 3231-42 |
| Linger RM, Lee-Sherick AB, DeRyckere D, et al. (2013) Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia. Blood. 122: 1599-609 |
| Jacobsen K, Linger R, Graham D. (2011) TYRO3 (TYRO3 protein tyrosine kinase) Atlas of Genetics and Cytogenetics in Oncology and Haematology |
| Linger RM, DeRyckere D, Brandão L, et al. (2009) Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia. Blood. 114: 2678-87 |